KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Gains from Investment Securities (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Gains from Investment Securities data on record, last reported at $365.9 million in Q4 2025.

  • For Q4 2025, Gains from Investment Securities changed N/A year-over-year to $365.9 million; the TTM value through Dec 2025 reached $369.9 million, changed N/A, while the annual FY2025 figure was $369.9 million, N/A changed from the prior year.
  • Gains from Investment Securities reached $365.9 million in Q4 2025 per VRTX's latest filing, up from -$5.6 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $365.9 million in Q4 2025 and bottomed at -$260.9 million in Q2 2025.
  • Average Gains from Investment Securities over 5 years is $29.0 million, with a median of $1.2 million recorded in 2023.
  • Peak YoY movement for Gains from Investment Securities: surged 7483.33% in 2021, then tumbled 7050.0% in 2022.
  • A 5-year view of Gains from Investment Securities shows it stood at -$137.3 million in 2021, then surged by 34.23% to -$90.3 million in 2022, then skyrocketed by 351.83% to $227.4 million in 2023, then plummeted by 99.87% to $300000.0 in 2024, then soared by 121866.67% to $365.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $365.9 million in Q4 2025, -$5.6 million in Q3 2025, and -$260.9 million in Q2 2025.